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a b s t r a c t
HIV-1 NL4-3 Vpu induces downregulation of cell surface CD155, a ligand for the DNAM-1 activating
receptor of NK and CD8þ T cells, to evade NK cell mediated immune response. Here we show that the
conserved alanine residues at positions 10, 14 and 18 in the TM domain of Vpu are required for
the efﬁcient downregulation of cell surface CD155. In contrast, the CK-2 phosphorylation sites and the
second α-helix in the cytoplasmic Vpu domain have no inﬂuence on the surface expression of CD155.
Thus, compared to Vpu's effect on CD4, NTB-A and tetherin, the Vpu mediated downregulation of CD155
is an independent Vpu function. We ﬁnally show that in contrast to other lentiviral strains, only Vpu and
Nef from HIV-1 M NL4-3 potently interfere with CD155 surface expression. Thus, Vpu seems to subvert
NK cell responses against HIV-1 infected T cells by modulation of receptors necessary for NK cell
activation.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The human immunodeﬁciency virus type 1 (HIV-1) accessory
protein Vpu is a 15–20 kDa oligomeric type 1 integral membrane
phosphoprotein (Cohen et al., 1988; Maldarelli et al., 1993; Strebel
et al., 1988), which is encoded exclusively by HIV-1 and related
simian immunodeﬁciency viruses (SIVs), but not by the majority of
SIVs and HIV-2. Vpu has been shown to induce the degradation of
newly synthesized CD4 by retaining it in the endoplasmic reticu-
lum (ER) (Magadan et al., 2010) and thereby targeting CD4 to the
ER-associated protein degradation (ERAD)-pathway. This speciﬁc
function of Vpu depends on the CK-2 phosphorylation sites in its
cytoplasmic domain (Binette et al., 2007; Magadan et al., 2010;
Schubert et al., 1998; Willey et al., 1992).
Furthermore, it has been shown that Vpu supports HIV-1 virion
release by counteracting the cellular restriction factor tetherin
(also known as CD317, BST-2 or HM1.24) (Neil et al., 2008; Van
Damme et al., 2008). Vpu induces an accumulation of tetherin in
the trans-Golgi network (TGN), which results in the downregula-
tion of cell surface tetherin (Dube et al., 2010; Schmidt et al., 2011).
Vpu and tetherin interact via their TM domains, and this interac-
tion is required for the efﬁcient downregulation of cell surface
tetherin (Banning et al., 2010; Dube et al., 2010; Iwabu et al., 2009;
Rong et al., 2009). Recently, it has been demonstrated that several
highly conserved residues in the TM domain of Vpu, particularly
Ala-10, Ala-14 and Ala-18, are required for efﬁcient downregula-
tion of tetherin from the cell surface (Skasko et al., 2012; Vigan
and Neil, 2010).
In addition to its role in tetherin antagonism and CD4 degrada-
tion, HIV-1 Vpu induces the downregulation of the co-activating
NK-cell receptor NK-cell, T-cell, B-cell antigen (NTB-A) (also termed
CD352 or SLAMF6) as well as the activating NK cell receptor CD155
(also termed polio virus receptor (PVR) or NECL-5) from the cell
surface to evade NK-cell mediated lysis of HIV-1 infected cells
(Matusali et al., 2012; Shah et al., 2010). Moreover, Vpu affects the
anterograde transport of newly synthesized NTB-A molecules by
retention of NTB-A within the Golgi-compartment (Bolduan et al.,
2013). With the exception of HIV-1 group N, the Vpu mediated
downregulation of cell surface NTB-A is conserved among diverse
HIV-1 and SIV strains (Bolduan et al., 2013). In contrast, it is
currently not known how Vpu downregulates CD155 or if this
function is conserved among different lentiviral Vpu variants.
CD155 is a nectin-like protein that serves as a ligand for the
DNAX accessory molecule-1 (DNAM-1) activating receptor of NK
and CD8þ T cells (Takai et al., 2008; Vassena et al., 2013), thereby
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triggering T and NK cell-mediated cytotoxicity (Matusali et al.,
2012; Shibuya et al., 1996). Interestingly, while HIV-1 Nef and Vpu
are required for optimal downregulation of cell surface CD155 to
avoid DNAM-1 mediated immune response against HIV-1 infected
cells (Matusali et al., 2012), HIV-1 Vpr induces an upregulation of
cell surface and steady state CD155 levels in HIV-1 infected CD4þ
T cells. As a consequence, the effect of Vpr seems to decrease the
anti-CD155 activity of HIV-1 Nef (Vassena et al., 2013).
In order to elucidate the importance of the TM domain of Vpu
in downregulating cell surface CD155, several well-established
Vpu TM mutants, particularly A10N, A14N and A18N, were
analyzed for their capability to affect the surface expression of
CD155. We show that the mutation of Ala-10, Ala-14 and Ala-18 to
asparagine impairs the ability of Vpu to downregulate cell surface
CD155. In contrast, the CK-2 phosphorylation sites and the second
α-helix in the cytoplasmic domain of Vpu have no inﬂuence on the
surface expression of CD155. Interestingly, the Vpu Δ23 mutant,
which lacks the second cytoplasmic α-helix, exhibits an attenu-
ated ability to downregulate cell surface tetherin and NTB-A
(Bolduan et al., 2013; Dube et al., 2009), but was fully active on
CD155. Thus, the downregulation of CD155 is an independent
function of Vpu and can be separated from its effects on CD4, NTB-
A or tetherin. Furthermore, we show that Vpu causes intracellular
accumulation of CD155 in perinuclear compartments and a Vpu
mutant, which is retained in the ER/cis Golgi, still interferes with
CD155 cell surface expression. Altogether, these data indicate that
Vpu might inhibit trafﬁcking of CD155 to the cell surface. Finally,
our data reveal that Vpu and Nef proteins derived from HIV-1 M
NL4-3 are most potent agonists of CD155 cell surface expression,
whereas those from other strains, except SIVgor CP2139, were
strongly attenuated. Thus, these results are in line with a model
suggesting that a variety of Vpu and Nef functions mediate HIV-1
immune evasion and add to the full pathogenic potential of HIV-1.
Results
Ala-10, Ala-14 and Ala-18 in the Vpu TM domain are critical for the
downregulation of cell surface CD155
Recently, it was shown that HIV-1 NL4-3 Vpu downregulates
cell surface CD155 to evade NK cell mediated immune response
against HIV-1 infected cells (Matusali et al., 2012). Moreover, the
randomization of Vpu's TM domain impairs its ability to affect the
surface expression of CD155 (Matusali et al., 2012). In order to
analyze the effect of Vpu's TM and cytoplasmic domain on the
surface expression of CD155, we analyzed speciﬁc Vpu TM and
cytoplasmic deletion mutants, which are summarized in Fig. 1.
HeLa cells, which constitutively express endogenous CD155, were
transfected with NL4-3 wt Vpu or mutants translated along with
GFP via an internal ribosomal entry site (Vpu-IRES-GFP) to
monitor transfected cells. 24 h post-transfection cells were har-
vested, stained for cell surface (Fig. 2A) and intracellular (Fig. 2B)
CD155 using a CD155 speciﬁc antibody, and analyzed by ﬂow
cytometry. The surface expression of CD155 in Vpu expressing
cells was calculated as the mean ﬂuorescence intensity (MFI) of
CD155 expression in GFP positive cells relative to GFP negative
cells. In addition, cells were lysed and the soluble protein fraction
was analyzed by Western blot (Fig. 2C). Fig. 2A shows that NL4-3
wt Vpu as well as the m2/6 mutant efﬁciently downregulate cell
surface CD155, indicating that the CK-2 phophorylation sites have
no inﬂuence on the surface expression of CD155. The C-terminal
deletion mutant Vpu Δ23, which exhibits a decreased localization
in the TGN (Dube et al., 2009; Pacyniak et al., 2005), and the Vpu
KKDQ mutant, which is retained in the ER and the cis-Golgi
compartment (Shikano and Li, 2003; Skasko et al., 2011; Vigan
and Neil, 2011), both downregulate CD155 to the same degree as
wt Vpu (Fig. 2A).
In contrast to the Vpu A7N mutant, the Vpu TM mutants A10N,
A14N and A18N were strongly attenuated in their ability to decrease
the surface expression of CD155, implying that this stretch of
conserved residues is critical for the Vpu induced downmodulation
of cell surface CD155. For control, the expression levels of all Vpu
proteins were comparable (Fig. 2C). In Fig. 2B, we analyzed the
ability of Vpu to affect the intracellular expression of CD155. Here
we show that neither wt Vpu nor any of the mutants does alter
steady state protein levels of CD155 (Fig. 2B).
Next, we analyzed the impact of Vpu's TM domain, particularly
A18, to affect the surface expression of CD155 in CD4þ SupT1 T
cells (Fig. 3). Thus, CD4þ SupT1 cells were infected with either
VSV-G pseudotyped Vpu deletion mutant HIV-1 NL4-3 Vpu Del-1,
HIV-1 NL4-3 wt, HIV-1 NL4-3 Vpu RD or HIV-1 NL4-3 Vpu A18H,
and surface expression of CD155 was analyzed by ﬂow cytometry.
As expected, HIV-1 NL4-3 wt was capable of inducing down-
regulation of CD155 from the cell surface (Fig. 3). However, the
Vpu deletion mutant HIV-1 NL4-3 Vpu Del-1 and the Vpu mutants
HIV-1 NL4-3 Vpu RD and HIV-1 NL4-3 Vpu A18H lost their ability
to induce efﬁcient downregulation of cell surface CD155 (Fig. 3).
These results suggest that alanine 18 in the TM domain of Vpu is
required to induce downregulation of cell surface CD155 also in
the context of infected CD4þ T cells.
In summary, these results suggest that the TM domain of Vpu,
particularly Ala-10, Ala-14 and Ala-18, is crucial for cell surface
downregulation of CD155, while the CK-2 phophorylation sites
and the second α-helix in the cytoplasmic domain of Vpu are
dispensable for this phenomenon.
NL4-3 Vpu alters the subcellular localization of CD155 by entrapment
in perinuclear compartments
Since NL4-3 wt Vpu induces downregulation of cell surface CD155,
we investigated by immunoﬂuorescence whether Vpu has an inﬂu-
ence on the subcellular localization of CD155. HeLa cells were
transfected with, NL4-3 Nef–YFP or NL4-3 Vpu- fusion proteins
(Banning et al., 2010) containing the indicated mutations A10N,
A14N, A18N or RD. 24 h post-transfection, cells were ﬁxed, permea-
bilized and stained for CD155. Conﬁrming the results shown in Fig. 2A,
Fig. 1. Schematic representation of wt Vpu (A) or Vpu mutants KKDQ (B), RD (C),
A7N (D), A10N (E), A14N (F), A18N (G), A18H (H), m26 (I) or Δ23 (J).
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Fig. 2. The TM domain, particularly A10N, A14N and A18N, of Vpu is required for the efﬁcient downregulation of cell surface CD155. HeLa cells were transfected with either
Vpu-IRES-GFP or mutants thereof. 24 h post-transfection, cells were harvested and either stained for surface CD155 (A) or intracellular CD155 (B) using a CD155 speciﬁc
antibody. Subsequently, cells were analyzed by ﬂow cytometry. Summary of relative CD155 surface (A) and intracellular (B) expression from 3 independent experiments is
given below. Mock indicates non-infected and unstained control cells. Values from three independent experiments were plotted and assessed for statistical signiﬁcance by
using the GrapPad Prism V5.0 software package (nnn; pr0.0005, 1 way ANOVAwith Dunnett's test). In addition, cells were lysed and analyzed by Western blot using anti-β-
actin, anti-GFP and anti-Vpu antibodies (C).
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Fig. 3. Downregulation of cell surface CD155 by Vpu in CD4þ Sup-T1 T cells. CD4þ Sup-T1 T cells were infected with either VSVG-pseudotyped HIV-1 NL4-3 Vpu Del-1, HIV-1
NL4-3 wt, HIV-1 NL4-3 Vpu RD or HIV-1 NL4-3 Vpu A18H. 2 days after infection the cells were harvested and stained for surface CD155, using a CD155-speciﬁc antibody.
Afterwards the cells were stained intracellularly for HIV-1 p24 antigen, using anti-p24-FITC speciﬁc antibody and analyzed by ﬂow cytometry. Values from three
independent experiments were plotted and assessed for statistical signiﬁcance by using the GrapPad Prism V5.0 software package (nnn; pr0.0005, 1 way ANOVA with
Dunnett's test), which is given below.
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the A10N, A14N, A18N and RD mutants do not inﬂuence the surface
expression of CD155 and do not induce intracellular accumulation of
CD155 (Fig. 4B). In contrast, NL4-3 Vpu and Nef colocalize with CD155
in the perinuclear compartment (Fig. 4A). Moreover, it was previously
shown that HIV-1 requires Vpu and Nef for optimal downregulation of
cell surface CD155 (Matusali et al., 2012). To investigate the individual
impact of NL4-3 Nef and Vpu on the subcellular localization of CD155
in the context of whole viral genome expression, HeLa cells were
transfected with HIV-1 proviral clones harboring single or combined
inactivating mutations in vpu and nef (Wildum et al., 2006). 24 h post-
transfection, cells were ﬁxed, permeabilized and stained for CD155
using anti-CD155 speciﬁc antibody. This experiment revealed in NL4-3
HIV-1 wt expressing cells that CD155 is signiﬁcantly entrapped in
perinuclear compartments (Fig. 5A and B). However, in the absence of
either Vpu or Nef, CD155 only partially localizes in perinuclear
compartments. In contrast, in the absence of Vpu and Nef, CD155
trafﬁcking to the cell surface is not affected (Fig. 5A and B).
Overall, these data show that HIV-1 Vpu and Nef are both
required to alter the subcellular localization of CD155 in peri-
nuclear compartments and thus interfere with the efﬁcient trans-
port of CD155 to the cell surface. Furthermore, perinuclear
accumulation of CD155 depends on the TM domain, particularly
A10N, A14N and A18N, of Vpu.
Lentiviral Vpu and Nef proteins differentially affect the surface
expression of CD155
It is currently unknown whether Vpu and Nef mediated down-
regulation of CD155 is conserved among different lentiviral Vpu
and Nef variants. Therefore, HeLa cells were transfected with
expression plasmids for AU1-tagged Vpu and Nef derived from
HIV-1 M NL4-3, SIVgsn 166, SIVcpz EK505, SIVgor CP2139, HIV-1 N
CK1.62 or HIV-1 P RBF168. 24 h post-transfection, cells were
harvested and stained for surface CD155 and analyzed by ﬂow
cytometry. In addition, cells were lysed and analyzed by Western
blot. In Fig. 6A it is shown that Vpu proteins from HIV-1 M NL4-3
and partially SIVgor CP2139 are capable of inducing downregula-
tion of cell surface CD155. In contrast, the Vpu proteins derived
from SIVgsn 166, SIVcpz EK505, HIV-1 N CK1.62 and HIV-1 P
RBF168 are strongly attenuated in their ability to affect the surface
expression of CD155 (Fig. 6A). Although Vpu derived from HIV-1 N
CK1.62 and HIV-1 P RBF168 are expressed at slightly lower levels
compared to HIV-1 M NL4-3 Vpu (Fig. 6A), it has been previously
shown that they are still functional in their anti-CD4 and tetherin
activity (Sauter et al., 2009). In addition, Vpu SIVcpz EK505 and
SIVgsn 166 are highly expressed but have no detectable effects on
cell surface CD155.
Moreover, Nef derived from HIV-1 M NL4-3 induces down-
regulation of cell surface CD155 (Fig. 6B). The HIV-1 Nef precursors
SIVcpz EK505 and SIVgor CP2139 exhibit an intermediate activity
on the surface expression of CD155. In contrast, the Nef proteins
derived from SIVgsn 166; HIV-1 N CK1.62 and HIV-1 P RBF168 are
strongly attenuated in CD155 downregulation (Fig. 6B). Thus, we
conclude that the Vpu and Nef mediated downregulation of cell
surface CD155 is not conserved among lentiviral Vpu proteins in
contrast to what is shown for CD4 and NTB-A (Bolduan et al., 2013;
Sauter et al., 2009). This further indicates that only HIV-1 M
evolved the capacity to evade the NK cell response with high
efﬁciency.
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Fig. 4. Sub-cellular distribution of CD155 in the presence of NL4-3 wt Nef, wt Vpu or mutants. (A) HeLa cells were transfected with either YFP, wt Nef, wt Vpu-, RD-, A10N,
A14N or A18N-YFP fusion proteins (green). 24 h post-transfection, cells were ﬁxed, permeabilized and stained for CD155 (red) using anti-CD155 speciﬁc antibody. (B) Values
for the ratio of CD155 levels at the plasma membrane (PM)/perinuclear area of 10 analyzed cells were plotted and assessed for statistical signiﬁcance by using the GrapPad
Prism V5.0 software package (nnn; pr0.0002, 1 way ANOVA with Dunnett's test). Scale bars: 4 mm.
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Discussion
In this study, we demonstrate that NL4-3 Vpu downregulates
the activating NK cell receptor CD155 from the cell surface by the
conserved alanine residues Ala-10, Ala-14 and Ala-18 of its TM
domain to evade NK cell mediated immune response against HIV-
1 infected cells. This is particularly important, because another
accessory protein HIV-1 NL4-3 Vpr upregulates the activating
NKG2D ligands (ULBP-1, ULBP-2) (Ward et al., 2009) and CD155
(Vassena et al., 2013) to the cell surface, altogether increasing the
susceptibility of HIV-1 infected cells for lysis by NK cells.
HIV-1 evolved complex strategies to evade immune response
against NK cells by modulation of cell surface molecules that can
activate NK cells. It was previously shown that NL4-3 Vpu down-
regulates the co-activating NK cell receptor NTB-A from the cell
surface, which depends on the TM as well as the second cyto-
plasmic domain of Vpu, leading to a decreased NK-cell mediated
degranulation and cytotoxicity (Bolduan et al., 2013; Shah et al.,
2010). Moreover, NL4-3 Nef interferes with the expression of the
ligand for the NKp44-activating NK-cell receptor by intracellular
retention in HIV-1 infected cells (Fausther-Bovendo et al., 2009). In
addition, Nef downregulates HLA-A and -B to evade CTL lysis but
not HLA-C and -E, which protect cells from killing by NKs (Cohen
et al., 1999). Furthermore, HIV-1 Nef is capable to downregulate
the ligands of the activating receptor NKG2D and inhibits natural
killer cell-mediated cytotoxicity (Cerboni et al., 2007; Norman
et al., 2011).
Thus, NL4-3 Vpu and Nef are necessary to prevent NK-cell
mediated response of HIV-1 infected cells and it has been demon-
strated that these two viral proteins are also required for optimal
downregulation of cell surface CD155 (Matusali et al., 2012).
Interestingly, it was shown that HIV-2, which lacks the vpu gene,
is not capable to affect the surface expression of CD155, suggesting
an evolutionary pressure on HIV-1 to keep the anti-CD155 activity
(Matusali et al., 2012). In contrast to Vpu, the molecular mechanism
of the Nef mediated downmodulation of CD155 is better deﬁned. Nef
uses the motifs DD175AA or LL165AA to downregulate CD4 mole-
cules from the cell surface, which is distinct from the Nef mediated
downregulation of cell surface CD155 (Matusali et al., 2012). How-
ever, the domains necessary for CD155 antagonism by Vpu are
currently completely unknown as well as the capacity of divergent
HIV-1 and SIV Nef and Vpu proteins to downregulate CD155.
We demonstrate that the CK-2 phosphorylation sites and the
second cytoplasmic α-helix have no inﬂuence on the surface
expression of CD155 (Fig. 2A and Table 1), suggesting that the
effect of CD155 by Vpu is an independent function compared to
CD4, NTB-A and tetherin. Matusali et al. (2012) suggest that the
YFP fusion protein NL4-3 Vpu m2/6, containing point mutations of
Ser-52 and Ser-56 to Asn in the cytoplasmic domain of Vpu, is
attenuated to downregulate cell surface CD155. We could conﬁrm
that the Vpu m2/6-YFP fusion protein is slightly attenuated
compared to wt Vpu (Fig. S1), but the pCG-Vpu m2/6 mutant
exhibits the same anti-CD155 activity as NL4-3 wt Vpu (Fig. 2A).
Thus, most likely the large YFP-tag somehow attenuates the anti-
CD155 activity of the Vpu m2/6 variant.
In addition, our data reveal that the Vpu-KKDQ mutant, which
is trapped in the ER/cis-Golgi compartment (Shikano and Li, 2003;
Vigan and Neil, 2011), is capable of inducing downregulation of
cell surface CD155 (Table 1), indicating that Vpu might inhibit
trafﬁcking of CD155 to the cell surface. A previous study demon-
strates the TM domain of NL4-3 Vpu is critical to affect the surface
expression of CD155 (Matusali et al., 2012). We extend these
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Fig. 5. NL4-3 HIV-1wt induces an accumulation of CD155 in perinuclear compartments. (A) HeLa cells were transfected with either pBR HIV-1 NL4-3 wt-IRES-GFP, pBR HIV-1
NL4-3 ΔNef-IRES-GFP, pBR HIV-1 NL4-3 ΔVpu-IRES-GFP or pBR HIV-1 NL4-3 ΔNefΔVpu-IRES-GFP (green). 24 h post-transfection, cells were ﬁxed, permeabilized and stained
for CD155 (red) using anti-CD155 speciﬁc antibody. (B) Values for the ratio of CD155 levels at the plasma membrane (PM)/perinuclear area of 10 analyzed cells were plotted
and assessed for statistical signiﬁcance by using the GrapPad Prism V5.0 software package (nnn; pr0.0002, 1 way ANOVA with Dunnett's test). Scale bars: 4 mm.
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ﬁndings and show that the conserved alanine residues at positions
10, 14 and 18 in the TM domain of NL4-3 Vpu are critical for the
downregulation of cell surface CD155 (Fig. 2A and Table 1). This
stretch of conserved residues localizes on one face of the α-helix
(Bolduan et al., 2013, 2011) and is required for the interaction and
consequently downregulation of cell surface tetherin (Skasko
et al., 2011; Vigan and Neil, 2010). In contrast, we could not detect
an interaction between NL4-3 Vpu and CD155 via co-
immunoprecipitation or FACS-FRET analysis (data not shown).
Moreover, we could clearly show by intracellular CD155 staining
that Vpu has no inﬂuence on the steady state levels of CD155
(Fig. 2B). Thus, the exact role of Ala-10, -14 and -18 to counteract
CD155 is still elusive thus far.
NL4-3 wt Vpu and Nef, which affect the surface expression of
CD155 (Matusali et al., 2012), induce an accumulation of CD155 in
perinuclear compartments (Fig. 4), indicating that Vpu might
interfere with the correct transport of CD155 to the cell surface,
which agrees with the activity of the Vpu-KKDQ mutant. Conse-
quently, the Vpu mutants RD, A10N, A14N and A18N are inactive to
downregulate cell surface CD155 and do not inﬂuence its sub-
cellular localization. Since HIV-1 requires Vpu and Nef for optimal
downregulation of cell surface CD155 (Matusali et al., 2012), we
investigated the individual impact of these proteins on CD155
Fig. 6. Effect of lentiviral Vpu and Nef proteins on the cell surface expression of CD155. (A) HeLa cells were transfected with either AU1-tagged Vpu or Nef of HIV-1 M NL4-3,
SIVgsn 166, SIVcpz EK505, SIVgor CP2139 or HIV-1 N CK1.62 HIV-1 P RBF168. 24 h post-transfection, cells were harvested and stained for surface CD155 using a CD155
speciﬁc antibody and analyzed by ﬂow cytometry. Summary of relative CD155 surface expression in presence of lentiviral Vpu (A) or Nef (B) proteins is given below. Values
from three independent experiments were plotted and assessed for statistical signiﬁcance by using the GrapPad Prism V5.0 software package (nnn; pr0.0005, 1 way ANOVA
with Dunnett's test). In addition, cells were lysed and analyzed by Western blot using anti-β-actin and anti-AU1 antibodies.
Table 1
Summary of anti-human Tetherin, CD4, NTB-A and CD155 activity of NL4-3 wt Vpu
and TM or cytoplasmic mutants (Banning et al., 2010; Bolduan et al., 2013, 2011;
Dube et al., 2010, 2009; Matusali et al., 2012; Neil et al., 2008; Shah et al., 2010;
Skasko et al., 2011, 2012; Van Damme et al., 2008; Vigan and Neil, 2010, 2011).
Tetherin CD4 NTB-A CD155
wt Vpu þ þ þ þ
Vpu-KKDQ  n.d.  þ
Vpu RD  þ  
Vpu A7N þ n.d. n.d. þ
Vpu A10N n.d. n.d. n.d. 
Vpu A14N  n.d. n.d. 
Vpu A18N  þ n.d. 
Vpu A18H  n.d.  
Vpu m2/6 þ /  þ þ
Vpu Δ23    þ
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localization. Our ﬁndings reveal that in cells expressing infectious
HIV-1 both Vpu and Nef are necessary to interfere with CD155
trafﬁcking and induce perinuclear CD155 accumulation (Fig. 5, B).
Of note, when analyzing a panel of diverse Vpu and Nef variants,
isolated from different lentiviral HIV-1 and SIV strains, only NL4-3
HIV-1 M was able to downregulate CD155 (Fig. 6 and Table 2). This
ﬁnding is in contrast to what is shown for Nef and Vpu mediated
modulation of CD4 (Sauter et al., 2009) and Vpu's activity against
NTB-A (Bolduan et al., 2013; Shah et al., 2010) as summarized in
Table 2. However, we can formally not exclude the possibility that
SIV derived Vpu and Nef proteins are active against their host
species derived CD155 proteins as it is the case for viral tetherin
antagonism (Sauter et al., 2009). Apart from that, Vpu and Nef from
HIV-1 N and P were also inactive against CD155. These are just two
isolates and conclusions have to be drawn with high caution.
Nevertheless, it is tempting to speculate that only HIV-1 M—the
pandemic AIDS virus—has evolved the full capacity to evade NK cell
response. Thus, NK cells could critically contribute to HIV-1 control,
and viral countermeasures to evade NK cell response might be a
determinant of HIV-1 pathogenicity. It will be highly interesting to
challenge these hypotheses in future studies.
Conclusion
Taken together, we demonstrate that NL4-3 Vpu downregulates
cell surface CD155 by the alanine residues 10, 14 and 18 of its TM
domain and induces an accumulation of CD155 in perinuclear
compartments. Moreover, only Vpu and Nef derived from HIV-1 M
NL4-3 exhibit the ability to downregulate cell surface CD155,
suggesting that this phenomenon is not conserved among lenti-
viral Vpu and Nef proteins of HIV-1 and SIV. HIV-1 interference
with CD155 expression in particular and the evasion from the
host's NK cell response in general seem to be important for the full
pathogenic potential of HIV-1 M.
Material and methods
Site-directed mutagenesis and plasmid constructions
Mutations of the HIV-1 M NL4-3 Vpu A7N and HIV-1 M NL4-3 Vpu
A10N plasmids were introduced by site-directed mutagenesis (Quick
change Kit, Stratagene) using oligonucleotides that contain the indi-
cated changes. For cloning of the pCG-HIV-1 M NL4-3 Vpu A7N and
pCG-HIV-1 M NL4-3 Vpu A10N mutants, the mutations were intro-
duced by PCR into the previously described pCG-IRES-GFP vector,
which expresses GFP from a bicistronic mRNA (Sauter et al., 2009;
Schindler et al., 2003). The pCG-HIV-1 MNL4-3 wt Vpu-AU1-IRES-GFP,
pCG-HIV-1 M NL4-3 Vpu RD-AU1-IRES-GFP, pCG-HIV-1 M NL4-3 Vpu
Δ23-AU1-IRES-GFP, pCG-HIV-1 M NL4-3 Vpu-KKDQ-AU1-IRES-GFP,
pCG-HIV-1 M NL4-3 Vpu A18N-AU1-IRES-GFP, pCG-HIV-1 M NL4-3
Vpu m2/6-IRES-GFP, pCG-nefSTOP-IRES-GFP, pCG-SIVgsn 166 Vpu-
AU1-IRES-GFP, pCG-SIVcpz EK505 Vpu-AU1-IRES-GFP, pCG-SIVgor
CP2139 Vpu-AU1-IRES-GFP, pCG-HIV-1 N CK1.62 Vpu-AU1-IRES-GFP,
pCG-HIV-1 P RBF168 Vpu-AU1-IRES-GFP, pCG-HIV-1 M NL4-3 wt Nef-
AU1-IRES-GFP, pCG-SIVgsn 166 Nef-AU1-IRES-GFP, pCG-SIVcpz EK505
Nef-AU1-IRES-GFP, pCG-SIVgor CP2139 Nef-AU1-IRES-GFP, pCG-HIV-1
N CK1.62 Nef-AU1-IRES-GFP, pCG-HIV-1 P RBF168 Nef-AU1-IRES-GFP,
pBR NL4-3 wt-IRES-GFP, NL4-3ΔNef-IRES-GFP, NL4-3ΔVpu-IRES-GFP
and NL4-3 ΔNefΔVpu-IRES-GFP, HIV-1 NL4-3 wt, HIV-1 NL4-3 Vpu
Del-1, HIV-1 NL4-3 Vpu A18H, HIV-1 NL4-3 Vpu RD plasmids were
already described (Banning et al., 2010; Bolduan et al., 2013, 2011;
Klimkait et al., 1990; Sauter et al., 2009; Schindler et al., 2010, 2003;
Wildum et al., 2006). The pEYFP NL4-3 wt Vpu, Vpu m2/6, Vpu A10N,
Vpu A14N, wt NL4-3 Nef, Vpu RD and Vpu A18N plasmids, encoding a
Vpu–YFP fusion protein were described elsewhere (Banning et al.,
2010; Bolduan et al., 2011).
Cell culture
HeLa cells were cultivated in Dulbecco's modiﬁed Eagle med-
ium (DMEM) supplemented with 10% heat inactivated fetal calf
serum (FCS) and 2 mM L-glutamine, 100 U ml1 penicillin and
100 mg ml1 streptomycin. SUP-T1 cells were maintained in RPMI
1640-FBS and were fed by replacing 50% of the medium at 2-day
intervals.
Western blot analysis
HeLa cells were transiently transfected using Lipofectamine
2000™ (Invitrogen) according to the manufacturer's protocol.
24 h post-transfection, cells were lysed in 0.5% NP-40 lysis buffer
(150 mM NaCl, 50 mMTris–HCl, 0.5% Nonidet P-40 and protease
inhibitor cocktail (Roche)). Cell lysates were cleared by centrifuga-
tion at 10.000 rpm at 4 1C for 5 min. NP-40 soluble proteins were
separated in 12% SDS/PAA gels according to Laemmli (1970),
transferred onto PVDF membranes (GE Healthcare) and probed
with speciﬁc antibodies, followed by enhanced chemilumines-
cence detection. For internal controls, blots were stripped and
re-incubated with the appropriate antibody.
HIV-1 infection of Sup-T1 T cells
For each infection, 3106 Sup-T1 T cells were infected with
VSV-G pseudotyped HIV-1 NL4-3 Vpu Del-1, HIV-1 NL4-3 wt, HIV-
1 NL4-3 Vpu RD and HIV-1 NL4-3 Vpu A18H. 2 days after infection,
cells were analyzed by ﬂow cytometry. Virus stocks were prepared
in 293 T cells transfected with VSV-G pseudotyped HIV-1 NL4-3
Vpu Del-1, HIV-1 NL4-3 wt, HIV-1 NL4-3 Vpu RD and HIV-1 NL4-3
Vpu A18H plasmid DNA. Virus-containing supernatants were
centrifuged at 1500g for 5 min.
Flow cytometry analysis of Vpu mediated downregulation of CD155
HeLa cells were transfected with the different pCG-Vpu-IRES-
GFP and pCG-Nef-IRES-GFP expression plasmids. 24 h post-trans-
fection, the cells were harvested and stained for surface and
intracellular CD155 using an anti-CD155 antibody (Bio Legend)
and chicken anti-mouse Alexa 633 conjugated secondary antibody
(Molecular Probes, Invitrogen). CD155 surface expression on GFP-
positive cells was then analyzed in a FACS LSRII using FACSDiva
software (BDBiosciences). Data analysis was performed using FACS
Express V3 software (DeNovo). Sup-T1 cells were infected with
VSV-G pseudotyped HIV-1 NL4-3 Vpu Del-1, HIV-1 NL4-3 wt, HIV-
1 NL4-3 Vpu RD and HIV-1 NL4-3 Vpu A18H. 2 days after infection,
cells were harvested and stained for surface and intracellular
CD155 using an anti-CD155 antibody (Bio Legend) and chicken
anti-mouse Alexa 633 conjugated secondary antibody (Molecular
Table 2
Summary of anti-human Tetherin, CD4, NTB-A and CD155 activity of Vpu proteins
derived from HIV-1 M NL4-3, SIVgsn 166, SIVcpz EK505, SIVgor CP2139 or HIV-1 N
CK1.62 HIV-1 P RBF168 isolates (Bolduan et al., 2013; Sauter et al., 2011, 2009).
Vpu alleles Tetherin CD4 NTB-A CD155
HIV-1 M NL4-3 þ þ þ þ
SIVgsn 166 þ þ þ 
SIVcpz EK505  þ þ 
SIVgor CP2139  þ þ þ /
HIV-1 N CK1.62 þ   
HIV-1 P RBF168  þ n.d. 
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Probes, Invitrogen). Afterwards, the cells were ﬁxed in 2% PFA,
permeabilized with 1% Saponin for 10 min at RT and blocked with
10% FCS for 20 min at RT. Subsequently, cells were stained with
p24-FITC antibody (Fischer Scientiﬁc) then analyzed in a
FACS LSRII.
Confocal and immunoﬂuorescence microscopy
HeLa cells were transfected with either YFP, NL4-3 Nef, NL4-3
Vpu, A10N, A14N, A18N- or RD–YFP fusion proteins, pBR NL4-3 wt-
IRES-GFP, pBR NL4-3 ΔNef-IRES-GFP, pBR NL4-3 ΔVpu-IRES-GFP
or pBR NL4-3 ΔNefΔVpu-IRES-GFP. 24 h post-transfection, cells
were ﬁxed in 3% formaldehyde for 20 min at RT, permeabilized
with either 0,1% Triton X-100 or 1% Saponin for 10 min. Subse-
quently, cells were stained for CD155 using a 1:100 dilution of
anti-CD155 speciﬁc antibody (Pierce) and 1:400 diluted goat anti-
mouse Alexa Fluor 633 conjugated secondary antibody (Molecular
Probes, Invitrogen). Spinning disc confocal microscopy was per-
formed with either a Nikon TiE equipped with the PerkinElmer
UltraView Vox system or Leica TCS SP5 confocal microscope.
Images were analyzed with either the Adobe Photoshop software
or the Volocity 6.3-software package (Perkin Elmer).
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